152 related articles for article (PubMed ID: 34649258)
1. Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study.
Abdel-Rahman O; Koski SL
Neuroendocrinology; 2022; 112(8):777-783. PubMed ID: 34649258
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
Puliafito I; Chillari F; Russo A; Cantale O; Sciacca D; Castorina L; Colarossi C; Franchina T; Vitale MP; Ricciardi GRR; Adamo V; Esposito F; Giuffrida D
Front Endocrinol (Lausanne); 2023; 14():1065599. PubMed ID: 36793289
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans.
Azar I; Yazdanpanah O; Jang H; Austin A; Kim S; Chi J; Alkassis S; Saha BK; Chopra A; Neu K; Mehdi S; Mamdani H
JAMA Netw Open; 2022 Oct; 5(10):e2237699. PubMed ID: 36264573
[TBL] [Abstract][Full Text] [Related]
4. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
5. Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer.
Sama S; Kerrigan K; Sinnott JA; Puri S; Akerley W; Haaland B; Patel S
Cancer Treat Res Commun; 2023; 35():100686. PubMed ID: 36736060
[TBL] [Abstract][Full Text] [Related]
6. Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer.
Reck M; Horn L; Novello S; Barlesi F; Albert I; Juhász E; Kowalski D; Robinet G; Cadranel J; Bidoli P; Chung J; Fritsch A; Drews U; Wagner A; Govindan R
J Thorac Oncol; 2019 Apr; 14(4):701-711. PubMed ID: 30677506
[TBL] [Abstract][Full Text] [Related]
7. Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients.
Hatfield LA; Huskamp HA; Lamont EB
J Oncol Pract; 2016 Jul; 12(7):666-73. PubMed ID: 27352949
[TBL] [Abstract][Full Text] [Related]
8. Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms.
Brandi G; Paragona M; Campana D; Brighi N; Bondi A; Pantaleo MA; Corbelli J; Barbera MA; Biasco G
J Chemother; 2018 Feb; 30(1):53-58. PubMed ID: 28641483
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcome after sequential chemotherapy with cisplatin-etoposide, amrubicin and nogitecan in patients with treatment-related pure small-cell neuroendocrine prostate cancer.
Ueki H; Terakawa T; Hara T; Hirata J; Jimbo N; Okamura Y; Bando Y; Furukawa J; Harada K; Nakano Y; Fujisawa M
Jpn J Clin Oncol; 2023 Jun; 53(6):522-529. PubMed ID: 36828781
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study.
Imai H; Saijo K; Kawamura Y; Kodera S; Komine K; Iwasaki T; Takenaga N; Kasahara Y; Ouchi K; Shirota H; Takahashi M; Ishioka C
Oncology; 2024; 102(5):359-367. PubMed ID: 37903486
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
[TBL] [Abstract][Full Text] [Related]
12. Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy.
Nio K; Arita S; Isobe T; Kusaba H; Kohashi K; Kajitani T; Tamura S; Hirano G; Mitsugi K; Makiyama A; Esaki T; Ariyama H; Oda Y; Akashi K; Baba E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):829-35. PubMed ID: 25702050
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
Steuer CE; Behera M; Ernani V; Higgins KA; Saba NF; Shin DM; Pakkala S; Pillai RN; Owonikoko TK; Curran WJ; Belani CP; Khuri FR; Ramalingam SS
JAMA Oncol; 2017 Aug; 3(8):1120-1129. PubMed ID: 27978552
[TBL] [Abstract][Full Text] [Related]
14. The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis.
Guan Y; Yao Q; Hao Y; Zeng X; Wang W; Gu X; Xiang J; Sun Y; Song Z
Cancer Med; 2023 Aug; 12(15):16011-16018. PubMed ID: 37351565
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in the Management of Small Cell Carcinoma of the Uterine Cervix.
Miyoshi AI; Ueda Y; Kurita T; Kimura T; Yoshino K
Anticancer Res; 2023 Apr; 43(4):1397-1405. PubMed ID: 36974776
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series.
Imai H; Shirota H; Okita A; Komine K; Saijo K; Takahashi M; Takahashi S; Takahashi M; Shimodaira H; Ishioka C
Chemotherapy; 2016; 61(3):111-6. PubMed ID: 26636658
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB
Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study.
Salvo G; Flores Legarreta A; Ramalingam P; Jhingran A; Bhosale P; Saab R; Gonzales NR; Chisholm GB; Frumovitz M
Int J Gynecol Cancer; 2023 Sep; 33(9):1359-1369. PubMed ID: 37567596
[TBL] [Abstract][Full Text] [Related]
20. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]